Ground-breaking aspirin trial extended

The ASPREE-XT trial will track outcomes, including cancer deaths

Thousands of elderly patients who took part in the landmark ASPREE trial of aspirin for primary prevention will continue to be monitored for a further five years in an observational study.

Researchers behind the Australian-led ASPREE-XT (Aspirin in Reducing Events in the Elderly – Extension) study will examine the health impacts of prolonged aspirin use on cancer, stroke, dementia and other aspects of ageing such as frailty.